Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISOPYRAMIDE PHOSPHATE vs PROCAINAMIDE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Treatment of life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter
Treatment of life-threatening ventricular arrhythmias,Atrial fibrillation,Atrial flutter,Paroxysmal supraventricular tachycardia
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 m L/min), requiring dose adjustment.
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., Cr Cl <30 m L/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Primarily hepatic metabolism via CYP3A4; approximately 40-60% excreted unchanged in urine.
Hepatic acetylation via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); CYP2D6 minor pathway.
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
50-65% bound to plasma proteins (primarily to alpha-1-acid glycoprotein, with lower affinity to albumin).
~15-20% bound to serum albumin and alpha-1-acid glycoprotein; low binding minimizes displacement interactions.
0.8-1.4 L/kg (extensive tissue distribution; higher in myocardial tissue than plasma).
Vd: 1.5-2.5 L/kg (total body water); extensive tissue distribution (e.g., heart, liver, kidneys); clinical meaning: large Vd indicates substantial extravascular distribution, requiring loading doses for rapid therapeutic effect.
Oral: 80-90% (immediate-release); 60-80% (sustained-release due to incomplete absorption).
Oral: 75-95% (immediate-release); IM: 100%; sustained-release oral: ~90% (relative to immediate-release).
GFR 30-50 m L/min: 100 mg every 8-12 hours; GFR 15-29 m L/min: 100 mg every 12-24 hours; GFR <15 m L/min or dialysis: 100 mg every 24 hours or 50 mg every 12 hours.
Cr Cl 10-50 m L/min: administer every 6-12 hours. Cr Cl <10 m L/min: administer every 8-24 hours. For IV: reduce maintenance infusion rate proportional to Cr Cl.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce by 75%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: avoid use or reduce dose by 50-75% with monitoring.
Children <1 year: 10-30 mg/kg/day divided every 6 hours; 1-4 years: 10-30 mg/kg/day divided every 6 hours; 4-12 years: 10-30 mg/kg/day divided every 6 hours; adolescents: same as adult dosing up to 400 mg/day.
Oral: 15-50 mg/kg/day divided every 3-6 hours. IV: Loading dose 15-18 mg/kg; maintenance 20-80 mcg/kg/min. Maximum: 100 mg/kg/day.
Start at low end of dosing range (100 mg every 6 hours) due to decreased renal function and increased sensitivity; monitor QTc interval and anticholinergic effects.
Start with lower doses (e.g., 250 mg oral every 6 hours) due to age-related renal decline. Monitor for hypotension and toxicity. Adjust based on Cr Cl.
Disopyramide has negative inotropic effects and may precipitate or exacerbate heart failure. Use with caution in patients with pre-existing heart failure or significant left ventricular dysfunction.
May cause severe blood dyscrasias (e.g., agranulocytosis, neutropenia, thrombocytopenia) and drug-induced lupus erythematosus.
May worsen or precipitate heart failure due to negative inotropy,Risk of proarrhythmia (e.g., torsades de pointes) especially with hypokalemia or bradycardia,Anticholinergic effects: urinary retention, dry mouth, blurred vision, constipation,May cause hypoglycemia in rare cases,Dose adjustment required in renal or hepatic impairment
Monitor CBC regularly; discontinue if blood dyscrasias occur. Prolonged QT interval risk; caution with other QT-prolonging drugs. May exacerbate heart failure or hypotension. Reduce dose in renal impairment.
Cardiogenic shock,Pre-existing second- or third-degree AV block (without pacemaker),Known hypersensitivity to disopyramide,Severe heart failure or left ventricular dysfunction
Complete heart block, second-degree AV block, torsade de pointes, systemic lupus erythematosus, hypersensitivity to procainamide or procaine.
Avoid grapefruit juice as it may increase disopyramide concentrations. Limit caffeine intake as it may worsen arrhythmias. Avoid high-fat meals as they may reduce absorption.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes) as hyperkalemia may increase proarrhythmic risk. Alcohol may exacerbate hypotension and cardiac effects.
Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uterine contractions, potentially causing preterm labor; reports of neonatal hypoglycemia and respiratory depression. Not recommended during pregnancy unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placental perfusion; use only if clearly needed. Risk of neonatal arrhythmias if used near term.
Disopyramide is excreted into breast milk with milk-to-plasma ratio of approximately 0.9. Infant exposure estimated at 2–6% of maternal weight-adjusted dose. Monitor infant for bradycardia, hypoglycemia, and apnea. Weigh benefits against potential risks.
Present in breast milk in low concentrations; M/P ratio approximately 0.4-0.6. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for bradycardia or hypotension.
Dose may require adjustment due to pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance, altered protein binding). Monitor serum disopyramide levels and therapeutic response; consider lower starting doses and titrate to effect.
No specific dose adjustments recommended; however, increased volume of distribution and renal clearance in pregnancy may require higher doses or more frequent administration to maintain therapeutic levels. Monitor drug levels closely.
Disopyramide is a class IA antiarrhythmic with significant negative inotropic and anticholinergic effects. Avoid in patients with heart failure, cardiogenic shock, or glaucoma. Dose adjustment required in renal impairment. Monitor QRS and QT intervals; proarrhythmia risk. May cause hypoglycemia in elderly or diabetic patients. Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Procainamide is a Class Ia antiarrhythmic. Monitor for lupus-like syndrome (arthralgias, rash) especially in slow acetylators; screen with ANA titer. Torsades de Pointes risk; monitor QTc. Maintain serum potassium >4.0 m Eq/L. Avoid in myasthenia gravis. Adjust dose in renal impairment.
Take exactly as prescribed; do not skip doses or double up.,Do not take with grapefruit juice.,Avoid alcohol and other CNS depressants.,Report symptoms of heart failure (shortness of breath, swelling) or arrhythmia (palpitations, syncope).,May cause dry mouth, blurred vision, urinary retention; use caution driving.,Monitor blood sugar if diabetic.,Do not stop abruptly without consulting your doctor.
Take exactly as prescribed; do not skip doses.,Report any joint pain, rash, fever, or unexplained bruising immediately.,Avoid driving if you experience dizziness or lightheadedness.,Notify your doctor if you have new or worsening shortness of breath or chest pain.,Do not stop taking abruptly; this may cause a serious irregular heartbeat.
"Disopyramide, a class Ia antiarrhythmic agent, prolongs the QT interval by inhibiting cardiac potassium channels, thereby increasing the risk of torsades de pointes. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), also has dose-dependent QT-prolonging effects, primarily through hERG channel blockade. Concomitant use synergistically lengthens the QT interval, predisposing patients to potentially fatal ventricular arrhythmias, especially in those with pre-existing risk factors such as hypokalemia, bradycardia, or genetic long QT syndrome."
"Disopyramide, a class Ia antiarrhythmic agent, prolongs ventricular repolarization by blocking cardiac sodium and potassium channels. Ezogabine, a potassium channel opener, also has dose-dependent effects on cardiac repolarization. Coadministration may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Disopyramide, a class Ia antiarrhythmic agent, may potentiate the hypoglycemic effects of cinoxacin, a quinolone antibiotic, by enhancing insulin secretion and increasing peripheral glucose uptake. This interaction can lead to clinically significant hypoglycemia, particularly in patients with diabetes mellitus or those concurrently using other hypoglycemic agents. Patients may experience symptoms such as diaphoresis, palpitations, confusion, or loss of consciousness if blood glucose levels drop precipitously."
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISOPYRAMIDE PHOSPHATE vs PROCAINAMIDE HYDROCHLORIDE, answered by our medical review team.
DISOPYRAMIDE PHOSPHATE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.. PROCAINAMIDE HYDROCHLORIDE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISOPYRAMIDE PHOSPHATE and PROCAINAMIDE HYDROCHLORIDE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISOPYRAMIDE PHOSPHATE is: 100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.. The standard adult dose of PROCAINAMIDE HYDROCHLORIDE is: Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISOPYRAMIDE PHOSPHATE and PROCAINAMIDE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISOPYRAMIDE PHOSPHATE is classified as Category D/X. Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uteri. PROCAINAMIDE HYDROCHLORIDE is classified as Category A/B. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placent. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.